



Company name: DAIICHI SANKYO COMPANY, LIMITED
 Representative: Sunao Manabe, Representative Director, President and CEO
 (Code no.: 4568, Prime Market, Tokyo Stock Exchange)
 Please address inquiries to Kentaro Asakura,
 Vice President, Corporate Communications Department
 Telephone: +81-3-6225-1126
<https://www.daiichisankyo.com>

Daiichi Sankyo Announces Changes to Representative Directors, Directors, and Audit & Supervisory Board Members

Tokyo, Japan - (May 19, 2022) – Daiichi Sankyo Company, Limited (hereinafter, the Company) today announced that its Board of Directors has approved changes to its Representative Directors, Directors, and Audit & Supervisory Board Members as follows. Appointments will be subject to approval at the Company’s 17th Annual General Meeting of Shareholders on June 27 and formal resolutions at a subsequent board meeting.

1. Changes to Representative Directors (as of June 27, 2022)
 Reason for change: Expiration of Representative Director’s term

(1) Appointed Representative Director

Name	Current Position	New Position
Shoji Hirashima	Director Senior Executive Officer Head of Japan Business Unit	Representative Director Senior Executive Officer Head of Japan Business Unit

(2) Retiring Representative Director

Name	Current Position	New Position
Satoru Kimura	Representative Director	Senior Adviser

2. Changes to Directors (as of June 27, 2022)

(1) New candidates for Directors

Name	Current Position
Takashi Fukuoka	Executive Officer, Head of Corporate Strategy Div.
Yasuhiro Komatsu	Chairman and Professor, Department of Healthcare Quality and Safety, Graduate School of Medicine, Gunma University Director, Department of Healthcare Quality and Safety, Gunma University Hospital Vice president (specially appointed), Gunma University Hospital

* Yasuhiro Komatsu is a new candidate for Outside Director as defined in Article 2-15 of the Companies Act.

(2) Retiring Directors

Name	Current Position
Satoru Kimura	Representative Director
Tsuguya Fukui	Outside Director

* Satoru Kimura will be appointed as a Senior Adviser.

3. Changes to Audit & Supervisory Board Members (as of June 27, 2022)

(1) Candidates for Outside Audit & Supervisory Board Members

Name	Current Position
Yukiko Imazu	Outside Audit & Supervisory Board Member
Mitsuhiro Matsumoto	(Former Commissioner-General of the National Police Agency)

* Yukiko Imazu and Mitsuhiro Matsumoto are candidates for Outside Audit & Supervisory Board Member as defined in Article 2-16 of the Companies Act.

(2) Retiring Outside Audit & Supervisory Board Member

Name	Current Position
Tateshi Higuchi	Outside Audit & Supervisory Board Member

Attachment

Curriculum Vitae

1. Appointed Representative Director

Shoji Hirashima: Born March 6, 1961

Current Position Held

Director, Senior Executive Officer, Head of Japan Business Unit, Daiichi Sankyo Co., Ltd.

Career Summary

- Apr. 1988 Joined Daiichi Pharmaceutical Company, Limited
- Apr. 2010 CEO, U3 Pharma GmbH
- Apr. 2015 Vice President, Corporate Strategy Department, Corporate Strategy Division of the Company
- Apr. 2016 Vice President of Corporate Strategy Department and Senior Director of Oncology Business Group, Corporate Strategy Division of the Company
- Apr. 2017 Corporate Officer, Vice President of Corporate Business Management Department, Corporate Strategy and Management Division
- Apr. 2019 Executive Officer, Head of Global Brand Strategy Division of the Company
- Apr. 2020 Senior Executive Officer, Head of Global Brand Strategy Division of the Company
- Jun. 2020 Director, Senior Executive Officer, Head of Global Brand Strategy Division of the Company
- Apr. 2021 Director, Senior Executive Officer, Head of Corporate Strategy Division of the Company
- Apr. 2022 Director, Senior Executive Officer, Head of Japan Business Unit of the Company (to present)

The number of shares of the Company Held: 64,090

2. Candidate for Director

Takashi Fukuoka: Born April 27, 1961

Current Position Held

Executive Officer, Head of Corporate Strategy Div., Daiichi Sankyo Co., Ltd.

Career Summary

- Apr. 1987 Joined Sankyo Company, Limited
- Apr. 2013 Vice President of Venture Science Laboratories, R&D Division of the Company
- Apr. 2019 Corporate Officer, Executive Vice President, R&D Affairs, Daiichi Sankyo, Inc.
- Apr. 2022 Executive Officer, Head of Corporate Strategy Division of the Company (to present)

Yasuhiro Komatsu: Born October 25, 1957

Current Position Held

Chairman and Professor, Department of Healthcare Quality and Safety, Graduate School of Medicine, Gunma University

Director, Department of Healthcare Quality and Safety, Gunma University Hospital

Vice president (specially appointed), Gunma University Hospital

Career Summary

- Aug. 1998 Chief, Department of nephrology, St. Luke's International Hospital
- Nov. 2007 Director, Kidney center. St. Luke's International Hospital
- Jan. 2011 Vice President, Chief Quality and Safety Officer, St. Luke's International Hospital
- Nov. 2017 Chairman and Professor, Department of Healthcare Quality and Safety, Graduate School of Medicine, Gunma University (to present)
- Nov. 2017 Director, Department of Healthcare Quality and Safety, Gunma University Hospital (to present)
- Apr. 2018 Vice president (specially appointed), Gunma University Hospital (to present)

3. Candidate for Outside Audit & Supervisory Board Member

Yukiko Imazu: Born July 28, 1968

Current Position Held

Partner, Attorney-at-Law, Anderson Mōri & Tomotsune

Career Summary

Apr.	1996	Joined Anderson Mōri (currently, Anderson Mōri & Tomotsune)
Jan.	2005	Partner, Attorney-at-Law, Anderson Mōri & Tomotsune (to present)
Apr.	2007	Associate Professor, Keio University Law School
Mar.	2014	Director of Ishibashi Foundation (to present)
Jun.	2018	Outside Audit & Supervisory Board Member of the Company (to present)

Mitsuhiro Matsumoto: Born March 21, 1961

Former Position Held

Commissioner-General, the National Police Agency

Career Summary

Apr.	1983	Joined the National Police Agency (NPA)
Oct.	2009	Chief, Fukushima Prefectural Police
Apr.	2012	Director, Personnel Division, Commissioner-General's Secretariat, NPA
Apr.	2013	Director-General, Public Security Department, Tokyo Metropolitan Police
Apr.	2014	Chief, Kanagawa Prefectural Police
Aug.	2015	Director-General, Foreign Affairs and Intelligence Department, NPA
Sep.	2016	Director-General, Security Bureau, NPA
Jan.	2018	Director-General, Commissioner-General's Secretariat, NPA
Sep.	2018	Deputy Commissioner-General, NPA
Jan.	2020	Commissioner-General, NPA
Sep.	2021	Retired from NPA

For Reference:

Directors and Audit & Supervisory Board Members after the election at the Ordinary General Meeting of Shareholders (as of June 27, 2022)

Name	Positions and Assignments
Sunao Manabe	Representative Director, President and CEO
Shoji Hirashima	Representative Director, Senior Executive Officer, Head of Japan Business Unit
Masahiko Ohtsuki	Director, Senior Executive Officer, Head of Digital Transformation Management Div.
Hiroyuki Okuzawa	Director, Senior Executive Officer, Head of Corporate Planning & Management Div., CFO
Takashi Fukuoka	Director, Executive Officer, Head of Corporate Strategy Div.
Noritaka Uji	Outside Director
Kazuaki Kama	Outside Director
Sawako Nohara	Outside Director
Yasuhiro Komatsu	Outside Director
Ryoichi Watanabe	Audit & Supervisory Board Member
Kenji Sato	Audit & Supervisory Board Member
Yukiko Imazu	Outside Audit & Supervisory Board Member
Masako Watanabe	Outside Audit & Supervisory Board Member
Mitsuhiro Matsumoto	Outside Audit & Supervisory Board Member

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.

Media Contacts:**Japan:**

Masashi Kawase

Daiichi Sankyo Co., Ltd.

kawase.masashi.a2@daiichisankyo.co.jp

+81 3 6225 1126 (office)

Investor Relations Contact:DaiichiSankyoIR@daiichisankyo.co.jp